XCancer

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Description:

Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline \[C-11\]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors and normal brain and explore how these patterns relate to MRI findings, treatments received, and clinical outcomes.

Sponsor:

Washington University School of Medicine

Phase:

Phase 2

Contacts:

Tammie L.S. Benzinger, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Tammie L.S. Benzinger, M.D., Ph.D. (CONTACT)

benzingert@wustl.edu

314-362-6110

Jayashree Rajamanickam (CONTACT)

jayashree.r@wustl.edu

314-273-6140

Government Study Link:

NCT07462507 - Click here to see study on

ClinicalTrials.gov

CS1P1

Isotope(s):
Target(s):
  • S1P1
Ligand Class: Small Molecules
Inclusion
  • Has a clinical, radiographic, or pathological diagnosis of primary or secondary CNS malignancy that has not been treated with radiotherapy
  • Capable of providing written informed consent OR having a legally authorized representative (LAR) to provide informed consent for volunteering to undergo research procedure
  • * Male or female, any race
  • Age ≥ 18 years
Exclusion
  • * Hypersensitivity to \[C-11\]-CS1P1 or any of its excipients
  • Women who are currently pregnant or breastfeeding
  • Contraindications to PET, CT or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
  • Severe claustrophobia that would require general anesthesia
  • Prior cranial radiotherapy